MX2021012449A - Metodo para tratar tumores. - Google Patents

Metodo para tratar tumores.

Info

Publication number
MX2021012449A
MX2021012449A MX2021012449A MX2021012449A MX2021012449A MX 2021012449 A MX2021012449 A MX 2021012449A MX 2021012449 A MX2021012449 A MX 2021012449A MX 2021012449 A MX2021012449 A MX 2021012449A MX 2021012449 A MX2021012449 A MX 2021012449A
Authority
MX
Mexico
Prior art keywords
treating tumours
treating
tumors
epoxytiglienone
abscopal
Prior art date
Application number
MX2021012449A
Other languages
English (en)
Spanish (es)
Inventor
Paul Warren Reddell
Victoria Anne Gordon
Glen Mathew Boyle
Peter Gordon Parsons
Jason Kingsley Cullen
Original Assignee
QBiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901280A external-priority patent/AU2019901280A0/en
Application filed by QBiotics Pty Ltd filed Critical QBiotics Pty Ltd
Publication of MX2021012449A publication Critical patent/MX2021012449A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021012449A 2019-04-12 2020-04-09 Metodo para tratar tumores. MX2021012449A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019901280A AU2019901280A0 (en) 2019-04-12 Method of Treatment
PCT/AU2020/050360 WO2020206504A1 (en) 2019-04-12 2020-04-09 Method of treating tumours

Publications (1)

Publication Number Publication Date
MX2021012449A true MX2021012449A (es) 2021-11-12

Family

ID=72752169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012449A MX2021012449A (es) 2019-04-12 2020-04-09 Metodo para tratar tumores.

Country Status (26)

Country Link
US (1) US12226391B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952858B1 (cg-RX-API-DMAC7.html)
JP (2) JP7900152B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210152531A (cg-RX-API-DMAC7.html)
CN (1) CN113924091A (cg-RX-API-DMAC7.html)
AU (1) AU2020256847B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020253A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136216C (cg-RX-API-DMAC7.html)
DK (1) DK3952858T3 (cg-RX-API-DMAC7.html)
EA (1) EA202192757A1 (cg-RX-API-DMAC7.html)
ES (1) ES3063750T3 (cg-RX-API-DMAC7.html)
FI (1) FI3952858T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260232T1 (cg-RX-API-DMAC7.html)
IL (1) IL287210B2 (cg-RX-API-DMAC7.html)
LT (1) LT3952858T (cg-RX-API-DMAC7.html)
MX (1) MX2021012449A (cg-RX-API-DMAC7.html)
MY (1) MY208979A (cg-RX-API-DMAC7.html)
PL (1) PL3952858T3 (cg-RX-API-DMAC7.html)
PT (1) PT3952858T (cg-RX-API-DMAC7.html)
RS (1) RS67777B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110599RA (cg-RX-API-DMAC7.html)
SI (1) SI3952858T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600066T1 (cg-RX-API-DMAC7.html)
UA (1) UA129840C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020206504A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108677B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
BR112021024716A2 (pt) 2019-06-19 2022-02-08 QBiotics Pty Ltd Ruptura de biofilme
CN118451065A (zh) * 2021-12-21 2024-08-06 Q生物股份有限公司 结晶中间体
EP4638430A4 (en) * 2022-12-21 2026-07-01 QBiotics Pty Ltd CRYSTALLINE FORMS AND THEIR PRODUCTION PROCESSES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
PT2986615T (pt) 2013-04-18 2019-03-22 Qbiotics Ltd Métodos e composições para a cicatrização de feridas
EP3490547A4 (en) * 2016-07-28 2020-04-01 QBiotics Pty Ltd TREATMENT METHOD
SG11201907891XA (en) * 2017-03-23 2019-09-27 QBiotics Pty Ltd Combination therapy for the treatment or prevention of tumours

Also Published As

Publication number Publication date
ZA202108677B (en) 2026-03-25
CA3136216A1 (en) 2020-10-15
SI3952858T1 (sl) 2026-04-30
WO2020206504A1 (en) 2020-10-15
AU2020256847A1 (en) 2021-11-11
IL287210B1 (en) 2025-03-01
UA129840C2 (uk) 2025-08-20
IL287210A (en) 2021-12-01
EA202192757A1 (ru) 2022-02-11
CN113924091A (zh) 2022-01-11
MY208979A (en) 2025-06-14
ES3063750T3 (en) 2026-04-20
FI3952858T3 (fi) 2026-02-18
US12226391B2 (en) 2025-02-18
RS67777B1 (sr) 2026-03-31
HRP20260232T1 (hr) 2026-03-27
SMT202600066T1 (it) 2026-03-09
LT3952858T (lt) 2026-04-10
US20220193023A1 (en) 2022-06-23
EP3952858A4 (en) 2022-05-25
SG11202110599RA (en) 2021-10-28
KR20210152531A (ko) 2021-12-15
EP3952858A1 (en) 2022-02-16
PT3952858T (pt) 2026-02-26
CA3136216C (en) 2024-01-16
AU2020256847B2 (en) 2025-05-15
IL287210B2 (en) 2025-07-01
EP3952858B1 (en) 2025-12-17
JP7900152B2 (ja) 2026-08-04
BR112021020253A2 (pt) 2021-12-07
JP2022528915A (ja) 2022-06-16
DK3952858T3 (da) 2026-02-23
PL3952858T3 (pl) 2026-03-30
JP2025060945A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
ES3063750T3 (en) Method of treating tumours
CO2018003542A2 (es) Anticuerpo anti-garp
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
CR20170014A (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
ZA201907225B (en) Treatment of her2 positive cancers
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
EA201791951A1 (ru) Продукты рилузола и их применение
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
NI201900105A (es) Terapia combinada para el cáncer de próstata
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2017012408A (es) Metodos para administrar inhibidores de glutaminasa.
PH12018501451A1 (en) Formulations for treating bladder cancer
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
MX390835B (es) Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientes
MX2017011298A (es) Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53.
MX386249B (es) Terapia tusc2 para usarse en el tratamiento de cáncer.
ECSP22085983A (es) Formulaciones farmacéuticas de acetato de abiraterona y niraparib
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.